Another lawsuit is lodged against Medtronic accusing its officers and directors of falsely inflating its stock value through off-label promotion of its Infuse bone growth protein.
Medtronic (NYSE:MDT) found itself at the center of another shareholder lawsuit accusing it of artificially boosting its stock price and forcing the company to repurchase more than $2.8 billion of its own shares at inflated rates.
In a lawsuit filed this week, a clutch of investors accuse Medtronic's top brass of making misleading statements in filings with the SEC, calls with analysts, press releases and other public statements to conceal that it was actively promoting off-label use of its Infuse bone growth protein, which was in turn causing problems for patients, according to court documents.
"Unbeknownst to shareholders, the company was risking adverse regulatory actions, investigations, lawsuits, and declining sales," according to the shareholders' complaint. "The improper statements and omissions have devastated Medtronic's credibility."
"Under the board's authorization, the company bought back more than $2,847,113,040 worth of its shares at a weighted average price of $50.39," according to the complaint. "Tellingly, this weighted average price is substantially higher than Medtronic's share price of $31.60 on November 18, 2008, when its true business health was revealed."
The lawsuit names Medtronic directors and executives, including former CEO Bill Hawkins and current CEO Omar Ishrak.
Hologic exceeds expectations again with its fiscal 2nd quarter, beating Wall Street's forecast and...
Rapidly advancing sensor technology may wind up making wearable device obsolete.
A Boston Scientific-sponsored study finds that replacing implantable cardiac devices due to battery...
A new analysis of more than 1,200 patients treated with Medtronic's Endurant AAA stent graft showed '...